Angiotensin-Converting Enzyme Inhibitors
Research News and Information

Sunday, November 22, 2009

Strict blood-pressure control and progression of renal failure in children.

20 Oct 2009 BACKGROUND: Although inhibition of the renin-angiotensin system delays the progression of renal failure in adults with chronic kidney disease, the blood-pressure target for optimal renal protection is controversial. We assessed the long-term ... Read more...

Clinical benefit of early reperfusion therapy in patients with ST-elevation myocardial infarction usually excluded from randomized clinical trials (results from the Maximal Individual Therapy in Acute Myocardial Infarction Plus [MITRA Plus] registry).

13 Oct 2009 Randomized clinical trials (RCTs) usually enroll selected patient populations that may not be representative for patients seen in everyday practice. Therefore, concerns have been raised regarding their external validity. For the present study we ... Read more...

Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure.

3 Oct 2009 BACKGROUND: Chronic kidney disease (CKD) is an established risk factor for poor outcomes in heart failure (HF). Whether proteinuria provides additional prognostic information is not known. Renin-angiotensin blockade medications improve outcomes in ... Read more...

Latest indexed articles for 'Angiotensin-Converting Enzyme Inhibitors'

These are the very latest articles for this heading:

• Angiotensin-converting enzyme inhibitor therapy at the time of coronary artery bypass surgery: when a friend turns mean-spirited. Nov 2009
• ALLHAT findings revisited in the context of subsequent analyses, other trials, and meta-analyses. 24 Oct 2009
• Blood-pressure control and delay in progression of kidney disease in children. 20 Oct 2009
• Strict blood-pressure control and progression of renal failure in children. 20 Oct 2009
• Clinical benefit of early reperfusion therapy in patients with ST-elevation myocardial infarction usually excluded from randomized clinical trials (results from the Maximal Individual Therapy in Acute Myocardial Infarction Plus [MITRA Plus] registry). 13 Oct 2009
• Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure. 3 Oct 2009
• Quinaprilat: a review of its pharmacokinetics, pharmacodynamics, toxicological data and clinical application. 29 Sep 2009
• Lack of association between ACE and bradykinin B2 receptor gene polymorphisms and ACE inhibitor-induced coughing in hypertensive Koreans. 29 Sep 2009
• Long-term stability of extemporaneously prepared captopril oral liquids in glass bottles. 29 Sep 2009
• Baseline differences in the HF-ACTION trial by sex. 29 Sep 2009
• Long-term effects of perindopril on left ventricular structure and function in patients with stable coronary artery disease: a conventional and Doppler tissue echocardiographic pilot study. 29 Sep 2009
• Renal and retinal effects of enalapril and losartan in type 1 diabetes. 29 Sep 2009
• Renal and retinal effects of enalapril and losartan in type 1 diabetes. 29 Sep 2009
• Risk of hyperkalemia in nondiabetic patients with chronic kidney disease receiving antihypertensive therapy. 26 Sep 2009
• [Hypertension in diabetes mellitus] 25 Sep 2009
• Regression of left ventricular mass by antihypertensive treatment: a meta-analysis of randomized comparative studies. 19 Sep 2009
• Effects of telmisartan, ramipril, and their combination on left ventricular hypertrophy in individuals at high vascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial and the Telmisartan Randomized Assessment Study in ACE Intolerant Subjects With Cardiovascular Disease. 19 Sep 2009
• Role of renin-angiotensin system blockade in patients with diabetes mellitus. 13 Sep 2009
• [Effects of antihypertensive drugs on glucose metabolism and cardiovascular events] 8 Sep 2009
• Angiotensin II, mechanotransduction, and pulsatile arterial hemodynamics in hypertension. 2 Sep 2009

See a longer list of these articles.

Technical information about 'Angiotensin-Converting Enzyme Inhibitors'

Definition: A class of drugs whose main indications are the treatment of hypertension and heart failure. They exert their hemodynamic effect mainly by inhibiting the renin-angiotensin system. They also modulate sympathetic nervous system activity and increase prostaglandin synthesis. They cause mainly vasodilation and mild natriuresis without affecting heart rate and contractility.

Registry Number: 0

Descriptor UI: D000806

Alternative terms: Angiotensin-Converting Enzyme Inhibitors; Angiotensin Converting Enzyme Inhibitors; Antagonists, Angiotensin-Converting Enzyme; Antagonists, Angiotensin Converting Enzyme; Angiotensin I-Converting Enzyme Inhibitors; Angiotensin I Converting Enzyme Inhibitors; Inhibitors, Angiotensin-Converting Enzyme; Enzyme Inhibitors, Angiotensin-Converting; Inhibitors, Angiotensin Converting Enzyme; ACE Inhibitors; Kininase II Antagonists; Inhibitors, Kininase II; Kininase II Inhibitors; Inhibitors, ACE; Angiotensin-Converting Enzyme Antagonists; Angiotensin Converting Enzyme Antagonists; Enzyme Antagonists, Angiotensin-Converting; Antagonists, Kininase II;

Allowable Qualifiers: administration & dosage; adverse effects; analysis; blood; cerebrospinal fluid; chemical synthesis; classification; diagnostic use; economics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; poisoning; radiation effects; standards; supply & distribution; therapeutic use; toxicity; urine; chemistry; contraindications; agonists;

Tree Number: D27.505.519.389.745.085;

Online Note: use TEPROTIDE to search ANGIOTENSIN I-CONVERTING ENZYME INHIBITOR 1991-93

History Note: 88; ANGIOTENSIN I-CONVERTING ENZYME INHIBITOR was see TEPROTIDE 1991-93

Technical Notes: protease inhib & antihypertensives; DF: ACE INHIB